Press Releases

Press Releases

Date Title  
May 10, 2022 Omeros Corporation Reports First Quarter 2022 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 10, 2022-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
May 04, 2022 Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
SEATTLE --(BUSINESS WIRE)--May 4, 2022-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2022 , on Tuesday, May 10, 2022 , after the market closes. Omeros management will host a conference call and
Apr 20, 2022 Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA
SEATTLE --(BUSINESS WIRE)--Apr. 20, 2022-- Omeros Corporation (Nasdaq: OMER) today announced the online publication of a manuscript detailing the results of its pivotal study assessing efficacy and safety of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic
Mar 01, 2022 Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 1, 2022-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
Feb 24, 2022 Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022
SEATTLE --(BUSINESS WIRE)--Feb. 24, 2022-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2021 , on Tuesday, March 1, 2022 , after the market closes.
Jan 19, 2022 Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
SEATTLE --(BUSINESS WIRE)--Jan. 19, 2022-- Omeros Corporation (Nasdaq: OMER) today confirmed that earlier this month the company submitted to the U.S. Food and Drug Administration (FDA) its response to the Agency’s Complete Response Letter (CRL) for narsoplimab in the treatment of hematopoietic